Viking Therapeutics 주식 (NASDAQ: VKTX)

에 대한 최신 뉴스 Viking Therapeutics (NASDAQ:VKTX) 주식

Viking Therapeutics

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking_therapeutics

Biotech

Technicals

Trading Ideas

General

VKTX

바이킹 테라퓨틱스(NASDAQ:VKTX)의 주가가 금요일 개장 전 잠재적인 데스 크로스 바로 위에서 맴돌고 있어 중요한 순간을 맞이하고 있다. 50일 이동평균선이 200일 이동평균선 아래로 떨어지는 이 불길한 기술적 패턴은 종종 약세 신호로 간주된다. 아직 확정되지는 않았지만, 주식의 궤적은 최근 몇 달 동안 이전의 상승에도 불구하고 주가에 대한 압박이 증가하고 있음을 시사한다.

바이킹 테라퓨틱스 주식, 체중 감량 흥분이 둔화되며 데스 크로스 형성 직전

ASTSpaceMobile.Screenshotvideo

Mid Cap

News

Movers

ASTS

BEAM

CLDX

GSHD

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IOVA

PEGA

PTGX

VSAT

다음은 지난주 큰 폭의 상승세를 보인 6개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? AST 스페이스모바일(NASDAQ:ASTS)의 주가는 회사가 첫 5개의 상용 위성을 성공적으로 완료하면서 47.88% 상승했다.

비아샛 및 AST 스페이스모바일은 지난주 최고 성과를 보여준 6개 중형주 중 일부 (7월 21일-7월 27일)

Stocks Photo by Phongphan on Shutterstock

Equities

Markets

NVDA

TSLA

수요일 미국 주요 지수는 크게 하락세로 마감했다. 다우존스 산업평균지수는 1.25% 하락한 39,853.87에, S&amp;P 500 지수는 2.3% 하락한 5,427.13에, 나스닥 지수는 3.6% 하락한 17,342.41에 마감했다. 이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 주요 종목들이다:

수요일 주목받은 주식 5종목: 엔비디아, 포드, 치폴레, 바이킹 테라퓨틱스, 테슬라

Viking Therapeutics Inc

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Overweight rating and announces Price Target of $104.

Price Target

Initiation

Analyst Ratings

Cantor Fitzgerald Initiates Coverage On Viking Therapeutics with Overweight Rating, Announces Price Target of $104

Truist Securities analyst Joon Lee reiterates Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and lowers the price target from $95 to $75.

Reiteration

Truist Securities Reiterates Buy on Viking Therapeutics, Lowers Price Target to $75

Morgan Stanley analyst Michael Ulz maintains Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Overweight and lowers the price target from $105 to $102.

Morgan Stanley Maintains Overweight on Viking Therapeutics, Lowers Price Target to $102

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and maintains $102 price target.

HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) released its first-quarter results after Wednesday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/04/n44964150/viking-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-update"> from the report.&nbsp;</a>
The Details:&nbsp;Viking Therapeutics reported quarterly losses of&nbsp;41 cents&nbsp;per share, which missed the analyst consensus estimate of&nbsp;losses of 34 cents.
The company said the increase in the quarterly net loss was primarily due to the increase in research and development expenses and general and administrative expenses compared to the same period in 2024.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
Research and development expenses were $41.4 million for the first quarter, compared to $24.1 million for the same period in 2024. The increase was primarily due to increased expenses related to manufacturing for the company&#8217;s drug candidates, clinical studies, stock-based compensation and salaries and benefits, partially offset by decreased expenses related to pre-clinical studies.
General and administrative expenses were $14.1 million for the first quarter compared to $10 million for the same period in 2024. The increase was primarily due to increased expenses related to legal and patent services, stock-based compensation and insurance, partially offset by a decrease in salaries and benefits.
As of March 31, 2025, Viking held cash, cash equivalents and short-term investments of $852 million, compared to $903 million as of the end of 2024.
&#8220;In the first quarter of 2025, Viking continued to build on the strong momentum achieved in 2024,&#8221; stated Brian Lian, Ph.D., CEO of Viking.
&#8220;Throughout the first quarter we continued to ramp up activities in support of the initiation of Phase 3 trials with the subcutaneous formulation of VK2735, which are on track to begin later this quarter. In addition, during the first quarter, we not only announced the initiation of the Phase 2 VENTURE-Oral Dosing trial evaluating the tablet formulation of VK2735, but also the completion of enrollment in this study,&#8221; Lian added.
VKTX Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Viking Therapeutics stock was down 1.12% after hours at $25.50 on Wednesday.&nbsp;&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

Earnings

Health Care

After-Hours Center

Viking Therapeutics Stock Dips After Q1 EPS Miss: Details

Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.34) by 20.59 percent. This is a 57.69 percent decrease over losses of $(0.26) per share from the same period last year.

Earnings Misses

Viking Therapeutics Q1 GAAP EPS $(0.41) Misses $(0.34) Estimate

AMTB

ASGN

BANC

BPOP

BRKL

BWFG

CACI

CBAN

CHDN

CHKP

COOP

CSLR

CVLG

New Oriental Education & Technology Group

EGBN

EPRT

GATX

GLPG

HBNC

HCSG

IMAX

INBK

KALU

KREF

LRCX

MTDR

ODFL

ORLY

OSBC

OTIS

PLXS

PTEN

SEIC

Earnings Scheduled For April 23, 2025

Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-23. Here's what investors need to know before the announcement.
Analysts estimate that Viking Therapeutics will report an earnings per share (EPS) of $-0.32. 
Investors in Viking Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.05, leading to a 6.09% drop in the share price on the subsequent day.
Here's a look at Viking Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.27</td>
<td>-0.25</td>
<td>-0.27</td>
<td>-0.28</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.32</td>
<td>-0.22</td>
<td>-0.20</td>
<td>-0.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>21.0%</td>
<td>28.000000000000004%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745344947_0.png" alt="eps graph" />
<h3>Viking Therapeutics Share Price Analysis</h3>
Shares of Viking Therapeutics were trading at $23.72 as of April 21. Over the last 52-week period, shares are down 61.43%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/VKTX/earnings">To track all earnings releases for Viking Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Viking Therapeutics

Viking Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NYSE">VKTX</a>) short percent of float has fallen 5.26% since its last report. The company recently reported that it has 25.62 million shares sold short, which is 27.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Viking Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745251217_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Viking Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Viking Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Viking Therapeutics's peer group average for short interest as a percentage of float is 13.52%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Viking Therapeutics?

WIIM

Viking Therapeutics shares are trading higher after Pfizer discontinued the development of danuglipron.

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>),&nbsp;&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stocks are trading higher on Monday.
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) announced on Monday that it will discontinue the development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">chronic weight management</a>.
A single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury, which resolved after discontinuation of danuglipron.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42827918/viking-therapeutics-structure-therapeutics-positioned-as-key-pharma-partners-for-weight-loss-products-analyst" rel="noreferrer noopener">Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst</a>
Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it&#8217;s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with weekly injections.
Eli Lilly is developing orforglipron, which could be the first small-molecule weight-loss pill when it launches in 2026. This would give Eli Lilly a two-year lead <a href="https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation" target="_blank" rel="noreferrer noopener">before rivals catch up</a>.
In March, Viking Therapeutics completed subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company&#8217;s dual agonist of the GLP-1 and glucose-dependent <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44490486/viking-therapeutics-announces-completion-of-enrollment-in-phase-2-venture-oral-dosing-trial-of-vk2" rel="noreferrer noopener">insulinotropic polypeptide (GIP) receptors</a>.
VK2375 is being developed in oral and subcutaneous formulations for various metabolic disorders, such as obesity. Viking expects to report data from the study in <a href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" target="_blank" rel="noreferrer noopener">the second half of 2025</a>.
Viking plans to initiate Phase 3 development with the subcutaneous formulation of VK2735 in the first half of 2025.
In June 2024, Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) unveiled 12-week topline obesity data from its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39144875/structure-therapeutics-obesity-candidate-is-very-competitive-to-eli-lillys-orforgli" target="_blank" rel="noreferrer noopener">Phase 2a study of GSBR-1290</a>.
In the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/g39133591/structure-therapeutics-reports-positive-topline-data-from-its-phase-2a-obesity-study-and-capsule-t" rel="noreferrer noopener">6.2% at 12 weeks</a>.&nbsp;
In July 2024, Roche Holdings AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39812408/roche-highlights-encouraging-data-from-newly-acquired-second-weight-loss-drug-candidate-in-early-" rel="noreferrer noopener">type 2 diabetes and obesity</a>.
The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks.
This data is better compared <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39817857/obesity-drugs-focused-stocks-tumble-on-wednesday-whats-going-on-with-eli-lilly-novo-nordisk-vikin" rel="noreferrer noopener">to existing competitors</a>.
In June 2023, Pfizer discontinued the clinical development of another GLP-1-RA candidate, lotiglipron (PF-07081532), due to pharmacokinetic data from Phase 1 studies and laboratory measurements of elevated&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35757948/what-are-pfizers-prospects-in-obesity-pill-market-analysts-say-optimism-cautiousness-surround-wit" rel="noreferrer noopener">transaminases (liver enzymes)</a>.
In March, Altimmune Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) unveiled the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential developments&nbsp;for its <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44330443/altimmune-expands-weight-loss-drug-pemvidutides-potential-to-alcohol-related-disorders" rel="noreferrer noopener">obesity drug, pemvidutide</a>.
Phase 2 trials for pemvidutide in AUD and ALD are expected to start in the second and third quarters of 2025, respectively.
Price Action: LLY stock is up 1.14% at $739.26, NVO stock is up 1.68% at $65.82, ALT stock is up 3.40% at $4.56, VKTX stock is up 13.5% at $25.21
GPCR stock is up 8.36% at $17.23 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44788755/bp-discovers-oil-at-far-south-prospect-in-deepwater-gulf-boosts-upstream-growth-outlook" target="_blank" rel="noreferrer noopener">BP Discovers Oil At Far South Prospect in Deepwater Gulf, Boosts Upstream Growth Outlook</a></li>
</ul>

Large Cap

GPCR

RHHBY

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Editor's Note: The headline has been updated to reflect that the stocks are moving higher.
U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Friday.
Shares of Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rose sharply in today's pre-market trading after the Trump administration announced tariff <a href="https://www.benzinga.com/quote/AAPL">exemptions for smartphones</a>.
Apple shares gained 5.8% to 209.56 in the pre-market trading session.
Here are some other stocks moving higher in pre-market trading.
<ul>
<li>Third Harmonic Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares jumped 36.8% to $4.98 in pre-market trading after the company announced a plan of liquidation and dissolution.</li>
<li>Theratechnologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) gained 32.5% to $2.57 in pre-market trading. Future Pak, on Friday, proposed to acquire the company for $255 million.</li>
<li>TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) gained 20% to $2.34 in pre-market trading following a 5% gain on Friday.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) rose 14.5% to $25.45 in pre-market trading after gaining 3% on Friday.</li>
<li>MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) rose 12% to $25.40 in pre-market trading. MP Materials will release its financial results for the first quarter, after the closing bell on Thursday, May 8.</li>
<li>Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) gained 8.8% to $65.76 in pre-market trading after the Trump administration excluded a range of technology products, including consumer electronics from the 145% reciprocal tariffs bucket.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) climbed 5.8% to $86.73 in pre-market trading &nbsp;after the Trump administration excluded a range of technology products, including consumer electronics from the 145% reciprocal tariffs bucket.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) rose 3% to $114.17 in pre-market trading after the Trump administration excluded a range of technology products, including consumer electronics from the 145% reciprocal tariffs bucket.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44759831/top-3-industrials-stocks-that-may-explode-in-april">Top 3 Industrials Stocks That May Explode In April</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

AAPL

DELL

THRD

THTX

Third Harmonic Bio, Apple, Dell And Other Big Stocks Moving Higher In Monday's Pre-Market Session (CORRECTED)

Goldman Sachs analyst Richard Law initiates coverage on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Neutral rating and announces Price Target of $30.

Goldman Sachs Initiates Coverage On Viking Therapeutics with Neutral Rating, Announces Price Target of $30

Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VKTX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Viking Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 62%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $342,498, and 2 are calls, for a total amount of $63,900.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $70.0 for Viking Therapeutics over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Viking Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Viking Therapeutics's substantial trades, within a strike price spectrum from $20.0 to $70.0 over the preceding 30 days.
<h3>Viking Therapeutics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743191131_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$8.2</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$32.50</td>
<td>$102.0K</td>
<td align="right">495</td>
<td align="right">213</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$8.2</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$32.50</td>
<td>$69.6K</td>
<td align="right">495</td>
<td align="right">87</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$20.65</td>
<td>$20.45</td>
<td>$20.65</td>
<td>$40.00</td>
<td>$61.9K</td>
<td align="right">49</td>
<td align="right">30</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$8.2</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$32.50</td>
<td>$39.6K</td>
<td align="right">495</td>
<td align="right">262</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$44.0</td>
<td>$42.9</td>
<td>$44.0</td>
<td>$70.00</td>
<td>$39.6K</td>
<td align="right">30</td>
<td align="right">9</td>
</tr>
</tbody>
</table>

<h3>About Viking Therapeutics</h3>
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
In light of the recent options history for Viking Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Viking Therapeutics</h3>
<ul>
<li>With a trading volume of 1,390,322, the price of VKTX is down by -2.51%, reaching $25.48.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 26 days from now.</li>
</ul>
<h3>Expert Opinions on Viking Therapeutics</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $102.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $102. 
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $102. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

A Closer Look at Viking Therapeutics's Options Market Dynamics

Viking Therapeutics Completes Enrollment In Phase 2 VENTURE-Oral Dosing Trial Of VK2735 Tablet Formulation For Patients With Obesity

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$24.00</td>
<td>$50.5K</td>
<td>2.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$30.00</td>
<td>$60.2K</td>
<td>2.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/28/25</td>
<td>$320.00</td>
<td>$473.7K</td>
<td>609</td>
<td>602</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$320.00</td>
<td>$312.3K</td>
<td>43</td>
<td>502</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$27.50</td>
<td>$35.0K</td>
<td>2.4K</td>
<td>469</td>
</tr>
<tr>
<td>GERN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1.00</td>
<td>$33.7K</td>
<td>413</td>
<td>397</td>
</tr>
<tr>
<td>EWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$30.00</td>
<td>$32.2K</td>
<td>5.4K</td>
<td>332</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$230.00</td>
<td>$53.6K</td>
<td>6.9K</td>
<td>295</td>
</tr>
<tr>
<td>CAH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$130.00</td>
<td>$44.2K</td>
<td>2.6K</td>
<td>188</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$64.9K</td>
<td>9.5K</td>
<td>167</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with neutral sentiment. It expires in 56 day(s) on May 16, 2025. Parties traded 200 contract(s) at a $24.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $50.5K, with a price of $253.0 per contract. There were 2012 open contracts at this strike prior to today, and today 2073 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be bearish, is expiring today. Parties traded 300 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $60.2K, with a price of $201.0 per contract. There were 2865 open contracts at this strike prior to today, and today 1625 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bullish sentiment. It expires in 7 day(s) on March 28, 2025. Parties traded 600 contract(s) at a $320.00 strike. This particular put needed to be split into 57 different trades to become filled. The total cost received by the writing party (or parties) was $473.7K, with a price of $779.0 per contract. There were 609 open contracts at this strike prior to today, and today 602 contract(s) were bought and sold. 
• Regarding HCA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), we observe a put option sweep with bearish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 474 contract(s) at a $320.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $312.3K, with a price of $660.0 per contract. There were 43 open contracts at this strike prior to today, and today 502 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option trade that happens to be bearish, is expiring today. Parties traded 20 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1750.0 per contract. There were 2499 open contracts at this strike prior to today, and today 469 contract(s) were bought and sold. 
• Regarding GERN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>), we observe a call option trade with bearish sentiment. It expires in 210 day(s) on October 17, 2025. Parties traded 397 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $33.7K, with a price of $85.0 per contract. There were 413 open contracts at this strike prior to today, and today 397 contract(s) were bought and sold. 
• Regarding EWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), we observe a call option sweep with bullish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 104 contract(s) at a $30.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $310.0 per contract. There were 5479 open contracts at this strike prior to today, and today 332 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 91 day(s) on June 20, 2025. This event was a transfer of 198 contract(s) at a $230.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $53.6K, with a price of $271.0 per contract. There were 6965 open contracts at this strike prior to today, and today 295 contract(s) were bought and sold. 
• For CAH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), we notice a call option sweep that happens to be bullish, is expiring today. Parties traded 137 contract(s) at a $130.00 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $44.2K, with a price of $325.0 per contract. There were 2600 open contracts at this strike prior to today, and today 188 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 91 day(s) on June 20, 2025. Parties traded 116 contract(s) at a $57.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $64.9K, with a price of $560.0 per contract. There were 9548 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

AKRO

AMGN

EWTX

GERN

10 Health Care Stocks Whale Activity In Today's Session

Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VKTX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Viking Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 62%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $315,085, and 2 are calls, for a total amount of $67,318.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $32.5 for Viking Therapeutics over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Viking Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Viking Therapeutics's whale trades within a strike price range from $25.0 to $32.5 in the last 30 days. 
<h3>Viking Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742577436_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$4.85</td>
<td>$4.75</td>
<td>$4.75</td>
<td>$30.00</td>
<td>$100.2K</td>
<td>3.2K</td>
<td>262</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.02</td>
<td>$1.71</td>
<td>$2.02</td>
<td>$30.00</td>
<td>$60.6K</td>
<td>2.8K</td>
<td>966</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.78</td>
<td>$1.35</td>
<td>$1.78</td>
<td>$30.00</td>
<td>$48.9K</td>
<td>2.8K</td>
<td>1.3K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.48</td>
<td>$1.4</td>
<td>$1.44</td>
<td>$32.50</td>
<td>$40.9K</td>
<td>3.7K</td>
<td>66</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.06</td>
<td>$1.57</td>
<td>$1.88</td>
<td>$30.00</td>
<td>$37.6K</td>
<td>2.8K</td>
<td>366</td>
</tr>
</tbody>
</table>

<h3>About Viking Therapeutics</h3>
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Having examined the options trading patterns of Viking Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Viking Therapeutics Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,145,610, the VKTX's price is down by -1.23%, now at $28.0. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 33 days.</li>
</ul>
<h3>Professional Analyst Ratings for Viking Therapeutics</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $102.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Viking Therapeutics options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Market Whales and Their Recent Bets on VKTX Options

High-rolling investors have positioned themselves bullish on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in VKTX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern.
The sentiment among these major traders is split, with 37% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $25,535, and 7 calls, totaling $353,860.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $77.5 for Viking Therapeutics during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Viking Therapeutics stands at 531.67, with a total volume reaching 1,808.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Viking Therapeutics, situated within the strike price corridor from $15.0 to $77.5, throughout the last 30 days.
<h3>Viking Therapeutics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741794336_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$9.8</td>
<td>$9.35</td>
<td>$9.6</td>
<td>$25.00</td>
<td>$96.0K</td>
<td>218</td>
<td align="right">101</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/04/25</td>
<td>$3.0</td>
<td>$1.89</td>
<td>$2.8</td>
<td>$30.00</td>
<td>$70.0K</td>
<td>534</td>
<td align="right">18</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.4</td>
<td>$0.98</td>
<td>$1.32</td>
<td>$40.00</td>
<td>$44.4K</td>
<td>1.0K</td>
<td align="right">802</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$3.9</td>
<td>$2.75</td>
<td>$2.98</td>
<td>$30.00</td>
<td>$44.4K</td>
<td>534</td>
<td align="right">376</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.4</td>
<td>$0.97</td>
<td>$1.31</td>
<td>$40.00</td>
<td>$44.1K</td>
<td>1.0K</td>
<td align="right">465</td>
</tr>
</tbody>
</table>

<h3>About Viking Therapeutics</h3>
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
In light of the recent options history for Viking Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Viking Therapeutics's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,579,799, the price of VKTX is up by 8.18%, reaching $28.69.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 42 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Viking Therapeutics</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $102.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Scotiabank has revised its rating downward to Sector Outperform, adjusting the price target to $102. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Behind the Scenes of Viking Therapeutics's Latest Options Trends

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

Small Cap

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025

Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735

Contracts

CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025

Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Akero Therapeutics

Alvotech

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

ImmunityBio

Immunovant

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Veracyte

Zai Lab Limited - American Depositary Shares

Zai Lab

Cantor Fitzgerald

Truist Securities

Morgan Stanley

HC Wainwright & Co.

Goldman Sachs

바이킹 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)의 주가가 금요일 개장 전 <a href="https://kr.benzinga.com/?s=%EB%8D%B0%EC%8A%A4+%ED%81%AC%EB%A1%9C%EC%8A%A4++" target="_blank" rel="noopener">잠재적인 데스 크로스</a> 바로 위에서 맴돌고 있어 중요한 순간을 맞이하고 있다.
50일 이동평균선이 200일 이동평균선 아래로 떨어지는 이 불길한 기술적 패턴은 종종 약세 신호로 간주된다. 아직 확정되지는 않았지만, 주식의 궤적은 최근 몇 달 동안 이전의 상승에도 불구하고 주가에 대한 압박이 증가하고 있음을 시사한다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-670051" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29072648/Screenshot-2024-11-29-at-5.05.57-PM.png" sizes="(max-width: 628px) 100vw, 628px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29072648/Screenshot-2024-11-29-at-5.05.57-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29072648/Screenshot-2024-11-29-at-5.05.57-PM-300x234.png 300w" alt="" width="628" height="490" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112924&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">차트는 Benzinga Pro를 사용하여 생성되었습니다.</a>
읽어보세요: <a href="https://www.benzinga.com/general/biotech/24/11/42192091/biden-proposes-medicare-medicaid-access-for-popular-weight-loss-drugs">바이든, 인기 있는 체중 감량 약물에 대한 메디케어, 메디케이드 접근 제안</a>
<h2 class="wp-block-heading">VKTX 주식: 상승에서 하락으로</h2>
VKTX 주식은 올해 초 체중 감량 약물 프로그램에 대한 낙관론으로 인해 급등했다. 그러나 이러한 열정은 사라졌고, 주가는 금요일 종가 기준으로 지난 한 달 동안 26.22%, 지난 6개월 동안 14.31% 하락했다.
금요일 개장 전 주가는 54.51달러로, 20일 및 50일 단순 이동 평균선(58.72달러 및 63.04달러) 아래에서 거래되고 있어 약세 추세를 나타낸다.
한편, 바이킹의 200일 단순 이동 평균선은 62.73달러에 위치하여 데스 크로스를 가깝게 만드는 좁은 간격을 형성하고 있다. 이러한 기술적 약점은 이동평균 수렴 발산(MACD) 지표가 -3.68로 음수이며, 상대 강도 지수(RSI)가 42.11로 하락세를 나타내어 시장의 상승 모멘텀이 약화되고 있음을 나타낸다.
<h2 class="wp-block-heading">무거운 도전 과제들</h2>
분석가들은 바이킹이 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)와 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)와 같은 대기업들이 지배하는 고수익 체중 감량 약물 시장에서 경쟁할 수 있는 능력에 대해 우려를 제기했다.
바이킹의 체중 감량 약물 후보들은 가능성을 보였지만, 경구용 및 주사형 버전 모두의 생산 확대는 <a href="https://www.investopedia.com/viking-therapeutics-stock-slips-after-obesity-drug-trial-results-8738997">비용이 많이 들고</a> 시간이 소요될 수 있어 단기적인 전망을 제한할 수 있다.
<h2 class="wp-block-heading">전망: 기술적 시험</h2>
다가오는 데스 크로스는 바이킹에 대한 광범위한 역풍을 반영하며, 섹터 전반의 문제로 인해 투자자 신뢰가 약화되고 있다. 그러나 바이킹이 유리한 임상 업데이트나 체중 감량 파이프라인에서의 전략적 진전을 발표하면 주식은 다시 기반을 다질 수 있다.
현재 VKTX가 중요한 기술적 붕괴의 경계에 서 있는 만큼 차트에 모든 시선이 집중되고 있다.
주가가 지지를 찾을 것인지 아니면 두려운 데스 크로스를 확정지을 것인지, 투자자들은 주의 깊게 지켜보고 있다.
주가 움직임: 바이킹 테라퓨틱스의 주식은 금요일 2.88% 하락한 52.94달러에 마감했다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42241785/us-futures-signal-gains-on-the-truncated-trading-day-will-december-witness-a-santa-claus-rally-analysts-decode">미국 주식은 11월을 높은 가격으로 마감할 가능성이 있음: 12월에 산타 랠리가 있을까요? 애널리스트들이 분석</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

다음은 지난주 큰 폭의 상승세를 보인 6개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
<ol>
<li>AST 스페이스모바일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)의 주가는 회사가 <a class="ticker" href="https://www.benzinga.com//node/39958682">첫 5개의 상용 위성</a>을 성공적으로 완료하면서 47.88% 상승했다.</li>
<li>구스헤드 인슈어런스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>)의 주가는 긍정적인 <a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">2분기</a> 실적에 힘입어 39.86% 상승했다.</li>
<li>비아샛(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>)의 주가는 30.78% 상승했다. 회사는 새로운 보고 부문 구조를 <a class="ticker" href="https://www.benzinga.com//node/39973735">발표</a>했다.</li>
<li>바이킹 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)의 주가는 <a href="https://www.benzinga.com//node/39966690" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">VK2735의 3단계 진출</a> 발표 이후 29.86% 상승했다.</li>
<li>빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>)의 주식은 HC 웨인라이트(Wainwright)가 매수 등급으로 해당 주식에 대한 커버리지를 시작하고 <a class="ticker" href="https://www.benzinga.com/quote/BEAM/analyst-ratings">80달러의 목표 주가를</a> 발표한 후 주가는 23.93% 상승했다.</li>
<li>셀덱스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>)의 주식은 19.72% 올랐다.</li>
</ol>
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%9c%a0%eb%8b%88%eb%b2%84%ec%85%9c-%ed%97%ac%ec%8a%a4-%eb%b0%8f-%eb%a1%9d%ed%9e%88%eb%93%9c-%eb%a7%88%ed%8b%b4%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc/" target="_blank" rel="noopener">유니버셜 헬스 및 록히드 마틴은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (7월 21일-7월 27일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ed%8f%ac%eb%93%9c-%ec%8a%a4%ed%85%94%eb%9e%80%ed%8b%b0%ec%8a%a4-%eb%b0%8f-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-12/" target="_blank" rel="noopener">포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일부터 7월 27일)</a></li>
</ul>
AST SpaceMobile을 통한 사진
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

수요일 미국 주요 지수는 크게 하락세로 마감했다. 다우존스 산업평균지수는 1.25% 하락한 39,853.87에, S&amp;P 500 지수는 2.3% 하락한 5,427.13에, 나스닥 지수는 3.6% 하락한 17,342.41에 마감했다.
이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 주요 종목들이다:
엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
엔비디아는 6.80% 하락한 114.25달러에 마감했다. 이날 장중 최고가는 119.95달러, 최저가는 113.44달러였다. 52주 신고가는 140.76달러, 52주 신저가는 39.23달러이다. 이 회사는 다른 미국 칩 주식과 함께 수요일에 상당한 매도세를 보였다. 이는 부분적으로 테슬라와 구글의 모회사 알파벳의 <a href="https://www.benzinga.com/news/24/07/39938971/chip-stocks-nvidia-amd-and-others-see-more-selloff-on-wednesday-whats-going-on" target="_blank" rel="noopener" data-google-interstitial="false">실망스러운 2분기 실적</a> 때문이었다.
포드 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)
포드의 주식은 1.16% 하락한 13.67달러에 마감했다. 이날 주식의 최고가는 13.88달러, 최저가는 13.59달러였다. 52주 신고가는 14.85달러, 52주 신저가는 9.63달러이다. 이 자동차 제조업체는 2분기 매출이 전년 대비 <a href="https://www.benzinga.com/news/earnings/24/07/39943178/ford-q2-earnings-highlights-revenue-beat-eps-miss-transit-vans-hit-record-ev-sales-fall-37" target="_blank" rel="noopener" data-google-interstitial="false">6%</a> 증가한 478억 달러를 기록했다고 보고했으며 이는 스트리트 컨센서스 추정치인 440억 달러를 넘어섰다.
참조 자료: <a href="https://www.benzinga.com/news/24/07/39925959/kim-jong-un-rejects-donald-trumps-friendship-claims-north-korea-says-we-do-not-care-expresses-nuclea?itm_source=parsely-api" target="_blank" rel="noopener noreferrer">포드의 2분기 실적</a>
치폴레 멕시칸 그릴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>)
치폴레의 주식은 51.78달러에 1.47% 하락하여 마감했다. 이날 주식의 최고가는 52.49달러, 최저가는 51.46달러였다. 52주 신고가는 69.26달러, 52주 신저가는 35.37달러이다. 이 회사는 2분기 매출이 전년 동기 대비 <a href="https://www.benzinga.com/news/earnings/24/07/39943336/chipotle-mexican-grill-q2-earnings-revenue-beat-eps-beat-comps-up-11-on-stronger-demand-trends-and-" target="_blank" rel="noopener" data-google-interstitial="false">18.2%</a> 증가한 29억 7천만 달러를 기록해 시장 예상치인 29억 4천만 달러를 넘어섰다고 보고했다.
바이킹 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)
바이킹의 주식은 2.19% 하락한 50.41달러에 마감했다. 이날 주식의 최고가는 52.18달러, 최저가는 50.27달러였다. 52주 신고가는 99.41달러, 52주 신저가는 8.28달러이다. 이 회사는 분기별 주당 손실을 <a href="https://www.benzinga.com/general/biotech/24/07/39944467/viking-therapeutics-stock-climbs-on-q2-eps-beat" target="_blank" rel="noopener" data-google-interstitial="false">20</a>센트로 보고했는데, 이는 분석가들의 합의 손실 추정치인 27센트를 25.93%나 앞선 것이다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라 주식은 12.33% 하락한 215.99달러에 마감했다. 이날 주식의 최고가는 225.99달러, 최저가는 214.71달러였다. 52주 신고가는 278.98달러, 52주 신저가는 138.8달러이다. 이 EV 거대 기업은 <a href="https://www.benzinga.com/news/24/07/39923738/tesla-reiterates-new-electric-vehicles-on-track-for-2025-but-ceo-elon-musk-refuses-to-divulge-detail" target="_blank" rel="noopener" data-google-interstitial="false">2025</a>년 상반기에 새로운 전기 자동차 생산을 시작할 계획을 다시 한번 밝혔다.
<div id="__next">
<div class="sc-hsexvf bvVSnk article-layout-wrapper">
<div class="sc-geERIb bmSvCo">
<div class="sc-dVraiA bhgqHR layout-content-container lg:px-0 mx-auto px-4 layout-container max-w-7xl">
<div class="main-content-container layout-container mx-auto">
<div class="layout-flex flex flex-col w-full items-start">
<div class="layout-main w-full overflow-hidden flex flex-grow flex-col justify-between">
<div id="node-39948172" class="sc-buPYkW iXuGvt article-content-body">
<div id="article-body" class="sc-iNCmvy cJZmSi article-content-body-only ">
<div class="sc-jEhMWw jPPXeB">

Photo by Phongphan on Shutterstock
Benzinga의 <a href="https://www.benzinga.com/markets/equities/24/07/39948172/nvidia-ford-chipotle-viking-therapeutics-tesla-why-these-5-stocks-are-on-investors-radars-today" target="_blank" rel="noopener" data-google-interstitial="false">최고 프리마켓 종목과 뉴스</a>를 통해 오늘의 거래를 준비하세요.
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 제작되었으며 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noopener noreferrer">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

바이킹 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)의 주가는 회사가 수요일에 2분기 재무 결과를 발표한 후 애프터마켓에서 20% 이상 급등했다. 보고서의 주요 <a href="https://www.benzinga.com/pressreleases/24/07/n39942075/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update">내용</a>은 다음과 같다.
주요 정보: 바이킹 테라퓨틱스는 분기별 손실을 주당 20센트로 보고했는데, 이는 애널리스트들의 합의된 손실 추정치인 27센트를 25.93%나 앞선 것이다.
바이킹은 2분기에 2,230만 달러의 순손실을 보고했으며, 2023년 같은 기간의 1,920만 달러 순손실과 비교된다. 2024년 6월 30일 종료된 3개월 동안 순손실 증가의 주요 원인은 앞서 언급한 연구 개발 비용 및 일반 관리비 증가 때문이며, 이는 2023년 같은 기간과 비교했을 때 증가된 이자 수익으로 부분적으로 상쇄되었다.
해당 분기 연구개발 비용은 2,380만 달러로 2023년 같은 기간의 1,390만 달러에 비해 증가했다. 바이킹은 이러한 증가가 주로 회사의 약물 후보에 대한 제조, 임상 연구, 전임상 연구, 급여 및 복리후생, 주식 기준 보상과 관련된 비용 증가로 인한 것이라고 말했다.
&#8220;2024년 상반기는 세 가지 다른 임상 시험의 성공적인 결과를 보고하고 각 프로그램의 다음 단계를 준비하기 시작하면서 회사의 파이프라인 프로그램에서 강력한 추진력을 얻었다&#8221;라고 바이킹의 CEO인 브라이언 리안(Brian Lian) 박사가 말했다.
&#8220;비만에 대한 VK2735의 2상 VENTURE 연구에서는 13주 동안 투약한 후 기초 체중에서 약 15%의 체중 감소와 유망한 안전성 및 내약성을 입증했다. FDA의 타입 C 회의에서 서면 피드백을 받은 후, 우리는 이 화합물을 3상 개발로 진행하고 있다. 현재 연말에 열릴 것으로 예상되는 2상 종료 회의를 준비 중이다&#8221;라고 리안이 덧붙였다.
VKTX 주가 움직임: <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>에 따르면, 수요일 바이킹의 주식은 애프터마켓에서 23.77% 급등한 62.39달러를 기록했다.
다음 기사 읽기 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39939280/whats-going-on-with-riot-platforms-stock">라이엇 플랫폼스 주식에 무슨 일이 일어나고 있나요?</a></li>
</ul>
Csaba Nagy의 이미지 (Pixabay에서)
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

바이킹 테라퓨틱스의 주식은 예상을 뛰어넘는 2분기 EPS로 시간외 거래에서 20% 이상 급등

S&amp;P 500과 나스닥 100 지수는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39618958/us-services-sector-activity-experiences-largest-contraction-in-over-4-years-gold-ra" target="_blank" rel="noopener" data-google-interstitial="false">2020년 5월 이후 최악의 위축</a>을 겪은 6월 서비스 부문 활동이 예상보다 크게 낮아지자 투자자들이 금리 인하에 대한 기대를 높이면서 목요일 사상 최고치를 경신했다.
CME 그룹의 페드워치(FedWatch) 도구에 따르면 9월 연방준비제도(연준)의 금리 인하 가능성은 65%에서 72%로 증가했다. 트레이더들은 연말까지 50bp(베이시스 포인트) 이상의 금리 인하 가격을 책정했다. 이는 연준이 두 번의 금리 인하를 시사한다.
특히 미국 동부 시간 오후 2시에 발표될 연방공개시장위원회(FOMC) 의사록을 앞두고 위험 심리가 강했다.
iShares Semiconductor ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NYSE">SOXX</a>)가 추적하는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)와 칩 제조 산업은 각각 3.7%와 1.9% 상승했다.
VanEck Gold Miners ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>)가 4.2% 상승하는 등 금 광산주 부문에서도 강한 상승세를 보였다. 이는 금속 가격 상승에 힘입어 올해 현재까지 가장 성과가 좋은 세션 중 하나를 기록했다.
금리 하락에 대한 기대감으로 금 가격은 1.4%, 은은 3.5%, 구리는 2.6% 상승했다.
국채 수익률은 10년물과 30년물 수익률이 모두 7bp 하락하는 등 급격하게 약세를 보였다. iShares 20+ Year Treasury Bond ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>)는 1.1% 상승해 6월 13일 이후 가장 높은 상승률을 기록했다.
그러나 크립토 시장은 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)이 60,450달러로 2.7% 하락했다.
<h3 class="wp-block-heading">주요 미국 지수와 ETF의 수요일 성과</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>주요 지수</td>
<td>가격</td>
<td>1일 변동률</td>
</tr>
<tr>
<td>나스닥 100</td>
<td>20,168.73</td>
<td>0.8%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,531.06</td>
<td>0.4%</td>
</tr>
<tr>
<td>러셀 2000</td>
<td>202.16</td>
<td>0.1 %</td>
</tr>
<tr>
<td>다우 존스</td>
<td>39,273.72</td>
<td>-0.1%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">동부시간 12:28 p.m. 기준</figcaption></figure>
<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent070324&amp;t=be2bearmibe3na1">Benzinga Pro</a>의 데이터에 따르면:
<ul>
<li>SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 0.3% 상승한 550.85달러로 마감했다.</li>
<li>SPDR 다우존스 산업평균 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)가 0.2% 하락한 392.45달러로 마감했다.</li>
<li>기술주 중심의 Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 0.8% 상승한 490.70달러를 기록했다.</li>
<li>Technology Discretionary Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)는 1.3% 상승했으며, 이에 비해 Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)는 1% 하락했다.</li>
</ul>
<h3 class="wp-block-heading">수요일 주식 변동:</h3>
<ul>
<li>체중 감량 약물 대기업인 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)와 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)는 매사추세츠 아이 앤드 이어(Massachusetts Eye and Ear)에서 실시한 연구에서 오젬픽(Ozempic)과 위고비(Wegovy)가 실명의 눈 질환 위험이 더 높은 것으로 나타난 후 각각 1.9%와 4% 하락했다. 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)과 바이킹 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)도 각각 1.9%, 2.2% 하락했다.</li>
<li>테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주가는 화요일부터 전기 자동차 제조업체의 분기별 납품 실적이 예상보다 좋은 이후 5.5% 상승하는 등 상승 모멘텀을 이어갔다.</li>
<li>기타 전기차 관련 주식도 상승세를 보였는데, 루시드 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>)가 8%, 아처 에비에이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>)가 15% 상승했다.</li>
<li>파라마운트 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)은 스카이댄스(Skydance)가 파라마운트의 지배 회사인 내셔널 어뮤즈먼트(National Amusements) 인수 거래에 다시 관심을 갖고 있다는 월스트리트 저널의 소문에 따라 7% 이상 급등했다.</li>
<li>콘스텔레이션 브랜드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>)는 지난 분기 매출이 예상보다 낮은 가운데, 4.4% 하락해 2023년 10월 이후 최악의 세션을 기록했다.</li>
</ul>

Cryptocurrency

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

ETFs

$BTC

ACHR

LCID

PARA

연준 회의록을 앞두고 금리 인하 낙관론에 S&P 500, 나스닥 100이 최고치 기록: 금, 채권 랠리

Comments

Viking Therapeutics

뉴스

에 대한 최신 뉴스 Viking Therapeutics (NASDAQ:VKTX) 주식

토요일, 11월 30, 2024

월요일, 7월 29, 2024

목요일, 7월 25, 2024

목요일, 7월 04, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌